BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 34449935)

  • 21. A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.
    Proudman D; Nellesen D; Gupta D; Adib D; Yang J; Mamlouk K
    Adv Ther; 2022 Apr; 39(4):1678-1696. PubMed ID: 35157216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TARC, a CC chemokine, is frequently expressed in classic Hodgkin's lymphoma but not in NLP Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and most cases of anaplastic large cell lymphoma.
    Peh SC; Kim LH; Poppema S
    Am J Surg Pathol; 2001 Jul; 25(7):925-9. PubMed ID: 11420464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features.
    Sarkozy C; Morschhauser F; Dubois S; Molina T; Michot JM; Cullières-Dartigues P; Suttle B; Karlin L; Le Gouill S; Picquenot JM; Dubois R; Tilly H; Herbaux C; Jardin F; Salles G; Ribrag V
    Clin Cancer Res; 2020 Jul; 26(13):3145-3153. PubMed ID: 32122924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives.
    Simeone N; Frezza AM; Zaffaroni N; Stacchiotti S
    Future Oncol; 2021 Apr; 17(10):1253-1263. PubMed ID: 33289402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy.
    Kazansky Y; Cameron D; Mueller HS; Demarest P; Zaffaroni N; Arrighetti N; Zuco V; Kuwahara Y; Somwar R; Ladanyi M; Qu R; de Stanchina E; Dela Cruz FS; Kung AL; Gounder MM; Kentsis A
    Cancer Discov; 2024 Jun; 14(6):965-981. PubMed ID: 38315003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of novel pyridone-benzamide derivatives possessing a 1-methyl-2-benzimidazolinone moiety as potent EZH2 inhibitors for the treatment of B-cell lymphomas.
    Wu D; Zeng X; Zhao Y; Qin M; Gong P
    Bioorg Med Chem; 2024 May; 105():117725. PubMed ID: 38640588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas.
    Knutson SK; Warholic NM; Johnston LD; Klaus CR; Wigle TJ; Iwanowicz D; Littlefield BA; Porter-Scott M; Smith JJ; Moyer MP; Copeland RA; Pollock RM; Kuntz KW; Raimondi A; Keilhack H
    PLoS One; 2014; 9(12):e111840. PubMed ID: 25493630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).
    Dockerill M; Gregson C; O' Donovan DH
    Expert Opin Ther Pat; 2021 Feb; 31(2):119-135. PubMed ID: 33103538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isothiocyanates Potentiate Tazemetostat-Induced Apoptosis by Modulating the Expression of Apoptotic Genes, Members of Polycomb Repressive Complex 2, and Levels of Tri-Methylating Lysine 27 at Histone 3 in Human Malignant Melanoma Cells.
    Anestopoulos I; Paraskevaidis I; Kyriakou S; Giova LE; Trafalis DT; Botaitis S; Franco R; Pappa A; Panayiotidis MI
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EZH2: a novel target for cancer treatment.
    Duan R; Du W; Guo W
    J Hematol Oncol; 2020 Jul; 13(1):104. PubMed ID: 32723346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.
    Morschhauser F; Tilly H; Chaidos A; McKay P; Phillips T; Assouline S; Batlevi CL; Campbell P; Ribrag V; Damaj GL; Dickinson M; Jurczak W; Kazmierczak M; Opat S; Radford J; Schmitt A; Yang J; Whalen J; Agarwal S; Adib D; Salles G
    Lancet Oncol; 2020 Nov; 21(11):1433-1442. PubMed ID: 33035457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EZH2-mediated inhibition of KLF14 expression promotes HSCs activation and liver fibrosis by downregulating PPARγ.
    Du Z; Liu M; Wang Z; Lin Z; Feng Y; Tian D; Xia L
    Cell Prolif; 2021 Jul; 54(7):e13072. PubMed ID: 34031939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AP-2α-Mediated Activation of E2F and EZH2 Drives Melanoma Metastasis.
    White JR; Thompson DT; Koch KE; Kiriazov BS; Beck AC; van der Heide DM; Grimm BG; Kulak MV; Weigel RJ
    Cancer Res; 2021 Sep; 81(17):4455-4470. PubMed ID: 34210752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
    Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
    Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The biological environment of Hodgkin's lymphoma and the role of the chemokine CCL17/TARC.
    Hnátková M; Mociková H; Trnený M; Zivný J
    Prague Med Rep; 2009; 110(1):35-41. PubMed ID: 19591376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. When to Use Targeted Therapy for the Treatment of Follicular Lymphoma.
    Nastoupil LJ
    Curr Hematol Malig Rep; 2021 Feb; 16(1):45-51. PubMed ID: 33797691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tazemetostat for the treatment of multiple types of hematological malignancies and solid tumors.
    Marsh S; Jimeno A
    Drugs Today (Barc); 2020 Jun; 56(6):377-387. PubMed ID: 32525136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma.
    Tong KI; Yoon S; Isaev K; Bakhtiari M; Lackraj T; He MY; Joynt J; Silva A; Xu MC; Privé GG; He HH; Tiedemann RE; Chavez EA; Chong LC; Boyle M; Scott DW; Steidl C; Kridel R
    Clin Cancer Res; 2021 Oct; 27(19):5401-5414. PubMed ID: 34168051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tazemetostat: First Approval.
    Hoy SM
    Drugs; 2020 Apr; 80(5):513-521. PubMed ID: 32166598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chromatin remodeling by the histone methyltransferase EZH2 drives lung pre-malignancy and is a target for cancer prevention.
    Tellez CS; Picchi MA; Juri D; Do K; Desai DH; Amin SG; Hutt JA; Filipczak PT; Belinsky SA
    Clin Epigenetics; 2021 Feb; 13(1):44. PubMed ID: 33632299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.